Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab in children and adolescents with heterozygous familial hypercholesterolemia
2017-001903-60Phase 3Completed
- Sponsor
- Sanofi
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of alirocumab in heterozygous familial hypercholesterolemia (HeFH) and hypercholesterolemia (3 arms), sponsored by Sanofi. Primary endpoint: Percent change in low-density lipoprotein cholesterol. Started May 2018; status: completed.
02
Drugs
alirocumab
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)hypercholesterolemia
Beyond the preview
Go deeper on 2017-001903-60.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001903-60.